JP2011137015A - 壊死性全腸炎の発生を減少させるための方法及び組成物 - Google Patents

壊死性全腸炎の発生を減少させるための方法及び組成物 Download PDF

Info

Publication number
JP2011137015A
JP2011137015A JP2011027692A JP2011027692A JP2011137015A JP 2011137015 A JP2011137015 A JP 2011137015A JP 2011027692 A JP2011027692 A JP 2011027692A JP 2011027692 A JP2011027692 A JP 2011027692A JP 2011137015 A JP2011137015 A JP 2011137015A
Authority
JP
Japan
Prior art keywords
acid
phospholipid
per
egg
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011027692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011137015A5 (enExample
Inventor
Susan E Carlson
スーザン・イー・カールソン
Debra L Ponder
デブラ・エル・ポンダー
Michael B Montalto
マイケル・ビイ・モンタルト
Margaret H Dohnalek
マーガレツト・エイチ・ドナレツク
John D Benson
ジヨン・デイ・ベンソン
David A Borror
デイビツド・エイ・ボラー
David V Diodato
デイビツド・ブイ・ダイオダート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
University of Tennessee Research Foundation
Original Assignee
Abbott Laboratories
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories, University of Tennessee Research Foundation filed Critical Abbott Laboratories
Publication of JP2011137015A publication Critical patent/JP2011137015A/ja
Publication of JP2011137015A5 publication Critical patent/JP2011137015A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2011027692A 1997-02-21 2011-02-10 壊死性全腸炎の発生を減少させるための方法及び組成物 Pending JP2011137015A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US08/804,700 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/825,314 1997-03-28
US08/943,576 1997-10-03
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP53687198A Division JP2001516343A (ja) 1997-02-21 1998-02-19 壊死性全腸炎の発生を減少させるための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2011137015A true JP2011137015A (ja) 2011-07-14
JP2011137015A5 JP2011137015A5 (enExample) 2012-04-26

Family

ID=27122714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011027692A Pending JP2011137015A (ja) 1997-02-21 2011-02-10 壊死性全腸炎の発生を減少させるための方法及び組成物

Country Status (5)

Country Link
US (1) US6080787A (enExample)
JP (1) JP2011137015A (enExample)
KR (1) KR100439166B1 (enExample)
AR (1) AR011160A1 (enExample)
IL (1) IL150490A (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
AU2002309856B2 (en) * 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP2275101A1 (en) * 2001-05-14 2011-01-19 Martek Biosciences Corporation Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2004002232A1 (en) * 2002-06-28 2004-01-08 Theuer Richard C Fat compositions for infant formula and methods therefor
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
EP1589834B1 (en) * 2003-02-05 2007-04-11 N.V. Nutricia Enteral composition for the prevention and/or treatment of sepsis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2530170A1 (en) * 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
GB2422373B (en) 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) * 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
AU2006251562B2 (en) * 2005-05-23 2012-03-22 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
WO2008081989A1 (ja) * 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
EP2200443B2 (en) * 2007-09-17 2021-06-30 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
ES2804258T3 (es) 2010-12-31 2021-02-05 Abbott Lab Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
CA2822490C (en) 2010-12-31 2020-03-31 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
ES2667393T3 (es) 2010-12-31 2018-05-10 Abbott Laboratories Oligosacáridos de leche humana para modular inflamación
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
MY166945A (en) 2010-12-31 2018-07-25 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
CN107019701B (zh) 2010-12-31 2020-07-28 雅培制药有限公司 使用人乳低聚糖来降低婴儿、幼儿或儿童的坏死性小肠结肠炎的发病率的方法
EP2734210B1 (en) 2011-07-22 2017-11-22 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CA2846603A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014078544A1 (en) * 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
BR112015014561A2 (pt) 2012-12-18 2017-07-11 Abbott Lab fortificante de leite humano concentrado líquido contendo proteína hipoalergênica e luteína
WO2017117121A1 (en) * 2015-12-28 2017-07-06 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946221A (ja) * 1982-04-12 1984-03-15 ボード、オブ、リージェンツ、ザ、ユニバーシティー、オブ、テキサス、システム 胃腸潰瘍病治療用医薬組成物
JPS63301824A (ja) * 1987-02-17 1988-12-08 ボード・オブ・リージェンツ、ザ・ユニバーシティー・オブ・テキサス・システム 極性および中性脂質混合物を含有する胃腸管保護用組成物および胃腸管保護方法
EP0311091A1 (de) * 1987-10-09 1989-04-12 B. Braun Melsungen AG Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
JPH02279628A (ja) * 1989-03-15 1990-11-15 Univ Texas Syst 極性脂質および中性脂質の新規組成物
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
WO1996000016A1 (fr) * 1994-06-27 1996-01-04 Institut De Recherche Biologique Nouvelles compositions dietetiques a base de phospholipides et leur utilisation comme complement nutritionnel
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) * 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
ES2157898T3 (es) * 1991-01-24 2001-09-01 Martek Corp Aceites microbianos y usos de los mismos.
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
ATE167983T1 (de) * 1994-10-05 1998-07-15 Milupa Gmbh & Co Kg Phospholipidhaltige fettmischung mit lcp- fettsäuren
US5917068A (en) * 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946221A (ja) * 1982-04-12 1984-03-15 ボード、オブ、リージェンツ、ザ、ユニバーシティー、オブ、テキサス、システム 胃腸潰瘍病治療用医薬組成物
JPS63301824A (ja) * 1987-02-17 1988-12-08 ボード・オブ・リージェンツ、ザ・ユニバーシティー・オブ・テキサス・システム 極性および中性脂質混合物を含有する胃腸管保護用組成物および胃腸管保護方法
EP0311091A1 (de) * 1987-10-09 1989-04-12 B. Braun Melsungen AG Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
JPH02279628A (ja) * 1989-03-15 1990-11-15 Univ Texas Syst 極性脂質および中性脂質の新規組成物
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
WO1996000016A1 (fr) * 1994-06-27 1996-01-04 Institut De Recherche Biologique Nouvelles compositions dietetiques a base de phospholipides et leur utilisation comme complement nutritionnel
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN4006003806; Ｎａｒａｂａ，　Ｈ．　ｅｔ　ａｌ．: Ｅｕｒｏｐｅａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ ｖｏｌ．３０２, 1996, ｐｐ．１１７-１２１ *
JPN4006003807; Ｓｕｎ，　Ｘ．　ｅｔ　ａｌ．: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　ｃｌｉｎｉｃａｌ　ｉｎｖｅｓｔｉｇａｔｉｏｎ ｖｏｌ．８１, 1988, ｐｐ．１３２８-１３３１ *
JPN4006003808; Ｍｉｃｈａｅｌ，　Ｓ．　ｅｔ　ａｌ．: Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ ｖｏｌ．９９, 1990, ｐｐ．９７９-９８６ *
JPN4006003809; Ｍｉｃｈａｅｌ，　Ｓ．　ｅｔ　ａｌ．: Ｐｅｄｉａｔｒｉｃ　Ｒｅｓｅａｒｃｈ ｖｏｌ．３１，ｎｏ．５, 1992, ｐｐ．４２８-４３４ *

Also Published As

Publication number Publication date
US6080787A (en) 2000-06-27
KR20000075539A (ko) 2000-12-15
AR011160A1 (es) 2000-08-02
KR100439166B1 (ko) 2004-07-07
IL150490A (en) 2007-05-15

Similar Documents

Publication Publication Date Title
US6306908B1 (en) Methods for reducing the incidence of necrotizing enterocolitis
US6080787A (en) Methods for reducing the incidence of necrotizing enterocolitis
US6036992A (en) Process of making an enteral formula containing long-chain polyunsaturated fatty acids
AU613420B2 (en) Dietary supplement utilizing omega-3/medium chain triglyceride mixtures
JPS61502816A (ja) ダイエット補足材及びダイエットにより感染作用を最小にさせる方法
CA2109611A1 (en) Phospholipids
WO2007058523A1 (en) Composition with docosapentaenoic acid
TWI749451B (zh) 包含ω脂肪酸的醫藥組合物及包含彼之輸液製劑
KR20100094490A (ko) 유아 영양을 위한 지질 혼합물
JPH07508720A (ja) 異化代謝の病気の影響を最小限にするための食餌療法用補給物としてのモノ不飽和脂肪
JP2525624B2 (ja) 多価不飽和脂肪酸配合育児用粉乳
CN115104731B (zh) 营养组合物以及包含所述营养组合物的食品
CN115191604B (zh) 一种营养组合物和包含营养组合物的食品及应用
HUP0104760A2 (hu) Eljárás és készítmény a bél épségének megtartására és helyreállítására
JPH10262607A (ja) 乳幼児用栄養組成物
HK1034033B (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
MXPA99007737A (en) Use of polyunsaturated fatty acids forreducing the incidence of necrotizing enterocolitis
CZ296899A3 (cs) Přípravky pro omezení výskytu nekrotizující enterokolitidy a způsob jejich výroby
UA66354C2 (en) Methods and compositions for reducing incidence of necrotizing enterocolitis

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110308

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140107